

SOUNDING BOARD

Precision Medicine — Personalized, Problematic, and Promising

J. Larry Jameson, M.D., Ph.D., and Dan L. Longo, M.D.

The growing recognition of precision medicine by clinicians, health systems, and the pharmaceutical industry, as well as by patients and policymakers,¹ reflects the emergence of a field that is accelerating rapidly and will leave a major imprint on the practice of medicine. In this article, we summarize the forces accelerating precision medicine, the challenges to its implementation, and the implications for clinical practice.

WHAT IS PRECISION MEDICINE?

The terms precision, personalized, and individualized medicine are often used interchangeably. Many physicians contend that they have always practiced individualized and personalized medicine. We agree and, for this reason, prefer the term precision medicine to emphasize the new aspects of this field, which is being driven by new diagnostics and therapeutics. We define precision medicine as treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from other patients with similar clinical presentations. Inherent in this definition is the goal of improving clinical outcomes for individual patients and minimizing unnecessary side effects for those less likely to have a response to a particular treatment.

Arguably, the principles of precision medicine have been a cornerstone of medical practice since the earliest efforts to classify disease and prescribe a specific treatment on the basis of a diagnosis. What is new, however, is the pace of advances in diagnostic and treatment options.

A few examples — some old and some new — illustrate the concepts of precision medicine. For many years, the management of infectious disease has pivoted on the identification of a causative organism and the selection of an effective antimicrobial agent. For bacterial infections, the field is mature, and the choice of antibiotic

is based on known or empirically determined drug sensitivities of the causative organism. However, the field of infectious diseases remains ripe for further development. Imagine the prospect of point-of-care identification of bacteria or viruses, ideally with their likely sensitivities. Appropriate treatments could be initiated sooner, sparing patients unnecessary exposure to ineffective or broad-spectrum drugs and ultimately reducing rates of antibiotic resistance. Another familiar example of precision medicine is the use of recombinant biologic agents as replacement therapies. The production of recombinant factors VIII and IX revolutionized the efficacy and safety of treating patients with hemophilia. However, a precise diagnosis of the type of hemophilia is required to inform the specific treatment. Gene therapy is now on the horizon for hemophilia, potentially providing stable, long-term therapeutic levels of the needed clotting factor.² More recently, testing for specific genetic abnormalities has been transforming the classification and treatment of cancer. For example, in lung cancer, the traditional classification that is based on anatomic and histologic criteria is being augmented by molecular testing of *EGFR*, *MET*, *RAS*, *ALK*, and other genetic markers. *ALK* fusion genes are relatively rare (<5%) in non-small-cell lung cancer, but clinical responses to targeted inhibitors (e.g., crizotinib) can be dramatic for tumors that harbor the rearrangement.³ Moreover, the exclusion of patients without these mutations who are unlikely to have a response to such inhibitors can minimize the exposure of patients to costly and potentially toxic therapies that are unlikely to help them. Selected additional examples of precision medicine are shown in Table 1.

TECHNOLOGICAL ADVANCES AS DRIVERS OF PRECISION MEDICINE

The convergence of genetics, informatics, and imaging, along with other technologies such as

Table 1. Examples of Conditions in Which Precision Medicine Has Been Used.*

Medical Field	Disease	Biomarker	Intervention
Cancer	Chronic myeloid leukemia	BCR-ABL	Imatinib ⁴
	Lung cancer	EML4-ALK	Crizotinib ³
Hematology	Thrombosis	Factor V Leiden	Avoid prothrombotic drugs ⁵
Infectious disease	HIV/AIDS	CD4+ T cells, HIV viral load	Highly active antiretroviral therapy ⁶
Cardiovascular disease	Coronary artery disease	CYP2C19	Clopidogrel ⁷
Pulmonary disease	Cystic fibrosis	G551D	Ivacaftor ⁸
Renal disease	Transplant rejection	Urinary gene signature	Antirejection drugs ⁹
Hepatology	Hepatitis C	Hepatitis C viral load	Direct-acting antiviral agents ¹⁰
Endocrine disease	Multiple endocrine neoplasia type 2	RET	Prophylactic thyroidectomy ¹¹
Metabolic disease	Hyperlipidemia	LDL cholesterol	Statins ¹²
Neurology	Autoimmune encephalitis	CXCL13	Immunotherapy ¹³
Psychiatry	Alcohol-use disorder	GRIK1	Topiramate ¹⁴
Pharmacogenomics	Smoking cessation	CYP2A6	Varenicline ¹⁵
Ophthalmology	Leber's congenital amaurosis	RPE65	Gene therapy ¹⁶

* In the biomarker column, proteins or genes that are probed to find the specific variants of interest are shown. AIDS denotes acquired immunodeficiency syndrome, HIV human immunodeficiency virus, and LDL low-density lipoprotein.

cell sorting, epigenetics, proteomics, and metabolomics, is rapidly expanding the scope of precision medicine by refining the classification of disease, often with important prognostic and treatment implications (Fig. 1).¹⁷

Among these new technologies, genetics and next-generation DNA sequencing methods are having the greatest effect. The prospect of sequencing whole exomes or genomes for less than \$1,000 reshapes our thinking about approaches to genetic testing.¹⁸ The clinical implications will be greatest when the results of genetic testing are actionable, thus informing prognosis or treatment.¹⁹ For example, the molecular diagnosis of multiple endocrine neoplasia type 2 allows prophylactic thyroidectomy and regular screening for medullary thyroid cancer, pheochromocytoma, and hyperparathyroidism in affected persons; it also spares unaffected family members from unnecessary screening.¹¹

Imaging is not always considered as part of precision medicine, yet it has profoundly changed how we treat patients. Many diagnoses can now be made with reasonable confidence on the basis of imaging, which spares patients from more invasive testing or unnecessary surgery. A genera-

tion ago, many patients with severe abdominal pain would undergo surgery to rule out appendicitis before rupture; now computed tomography and ultrasonography provide greater sensitivity and specificity in the preoperative diagnosis of appendicitis.²⁰ Positron-emission tomography provides an additional means of detecting metabolically active cancer that is not readily seen with more traditional imaging and is being used to guide management decisions in response-adapted treatment programs for Hodgkin's lymphoma.²¹

Electronic health records contain a rich database of clinical information. In the future, algorithms will be developed to identify patients with disease risk factors (e.g., for patients with diabetes and elevated low-density lipoprotein cholesterol levels who are not taking a statin) or with a need for guideline-based screening (e.g., colonoscopy on the basis of age and family history) or to apply pharmacogenetic guidelines to assist with drug selection and administration.²² As the costs of genetic testing fall, electronic health records can be prepopulated with relevant genetic or pharmacogenomic data, providing clinicians with actionable information about which patients are positive for factor V Leiden or


are unable to metabolize the prodrug clopidogrel.⁷ With appropriate protections, eligible patients can be identified for clinical trials. None of these approaches will replace physician judgment about individual patients. Among other concerns, medical records contain errors and will not always contain relevant information important for treating a particular patient.

PRECISION MEDICINE AND DISRUPTIVE CHANGE IN THE PRACTICE OF MEDICINE


Patients, physicians, health systems, payers, and the diagnostics and pharmaceutical industries share interests in precision medicine, although such interests are not fully aligned (Fig. 1). Patients seek a clearer understanding of their disease, its prognosis, and the most effective treatment in terms of efficacy and side effects. Physicians and health systems share these interests but also must balance individual patient needs with management of overall health care utilization. Payers are concerned that new diagnostic tests and drugs will drive up health care expenditures and remain skeptical that these costs will be offset by more selective use and fewer side effects. The pharmaceutical industry seeks new drug opportunities, but often such drugs replace existing and profitable therapies. Thus, precision medicine is a classic example of disruptive innovation, defined as a circumstance in which an innovation threatens to revolutionize an existing standard (e.g., when digital photography rapidly replaced film photography).²³ There is a sweet spot where the interests of various stakeholders in the health care sector converge — it is the rigorous evaluation of efficacy, safety, and cost-effectiveness, all performed with an open mind about whether the tools of precision medicine provide value.²⁴

CHALLENGES FOR PRECISION MEDICINE

Perhaps the most daunting challenge for precision medicine is to manage the complexity associated with the progressively refined nosology (classification) of disease. Medicine has a long history of being divided into “lumpers and splitters”; lumpers tend to group related entities together, and splitters tend to apply more precise



definitions and thereby define more discrete entities. The advances in genetics and biomarkers will shift this balance in favor of the splitters. Leber’s congenital amaurosis can be caused by mutations in at least 14 genes. This phenomenon of locus heterogeneity has historically been the realm of geneticists. However, the gene-replacement strategy for Leber’s congenital amaurosis involves viral vector delivery and expression of a specific missing protein, RPE65, encoded by only 1 of these genes. This example foreshadows how more refined disease classification may lead to expanded decision algorithms and treatment options. On the other hand, disorders of particular pathways can be associated with myriad diseases



(Fig. 1). Mutations in the gene that encodes nuclear lamins (*LMNA*) in patients with so-called laminopathies can cause cardiomyopathy, muscular dystrophy, lipodystrophy, and progeria, among other conditions,²⁵ which highlights the challenge of predicting how abnormalities in a particular pathway will translate into disease. In addition to the increasing complexity of disease classification, a stunning number of new genetic alterations are being uncovered by next-generation sequencing. Although some of these mutations are clearly associated with disease, it is difficult to evaluate the role, if any, for many of the genetic variants.¹⁹

How can physicians adapt to this daunting explosion of information and the associated clinical guidelines (Fig. 2)? Memorization no longer serves this function. Increasingly, we must use informatics to assist us — not for replacing judgment but for providing facts. Indeed, primary care providers may have the most challenging

role in precision medicine. They stand on the front lines of the clinical care delivery system with a mandate to prevent disease, identify early signs of disease, and navigate referral paths that now have many more branches as a result of precision medicine. Increasingly, referral pathways will be needed to help connect selected patients to an expert with increased access to the emerging data and clinical guidelines.

Better biomarkers are needed to assist with disease detection and to help guide treatment, particularly for common acquired conditions without a strong genetic predisposition. Efforts to identify biomarkers for concussion,²⁶ imaging tests to detect Alzheimer's disease,²⁷ and circulating tumor markers²⁸ exemplify the clinical need for such diagnostic tools. The financial incentives to create new diagnostic tests are not as strong as those to create new drugs, despite the fact that diagnostics and therapeutics are inextricably linked. Controversies about the most

effective use of mammography and testing for prostate-specific antigen serve as a reminder of the challenges associated with establishing clinical guidelines, even when markers are sensitive and specific and have clear utility in selected patients.

FUTURE OPPORTUNITIES
FOR PRECISION MEDICINE

In addition to medications that target altered genetic pathways in cancer, such as imatinib for patients with chronic myeloid leukemia who have a *BCR-ABL* mutation⁴ or vemurafenib for those with melanoma or thyroid cancer who carry the *BRAF* V600E variant,²⁹ there is growing interest in targeted immunotherapies for cancer. Such therapies include antibodies against tumor pathways (e.g., trastuzumab against the tyrosine kinase ERBB2 [HER2])³⁰ or immune checkpoint pathways (e.g., nivolumab against PD-1)³¹ and the use of autologous T cells engineered to target specific antigens (e.g., CD19 on B-cell cancers).³² Of note, these immunotherapy approaches require matching known antigens or pathways with the antibodies or the engineered T cells. Thus, the principle of coupling diagnostics and therapeutics will also be a major feature of immunotherapy.

Advances in DNA sequencing have enabled studies of the microbiome, a surprisingly large ecosystem embedded on the surface of our skin and mucosal tracts. Emerging evidence suggests that the composition of a person's microbiome is a combination of innate immunity, introduction to organisms early in life, diet, and exposure to antibiotics and other environmental factors. Studies examining the microbiome in obesity, cardiovascular disease, cystic fibrosis, inflammatory bowel disease, skin disorders, cancer risk, and autism provide an indication of the level of interest in this emerging field, which may offer opportunities for individualized interventions.³³

Another provocative opportunity in precision medicine is the use of technology to assist with acute interventions in individual patients. A well-known example is the use of automated defibrillators to detect and interrupt cardiac arrhythmias. One can imagine analogous opportunities in epilepsy or hypoglycemia. Can we develop sensors or biomarkers to better predict premature labor or preeclampsia? As mobile technology is used to assist with health monitoring and

becomes more fully integrated with health records, can it be used to detect mood swings or pathologic skin lesions and to serve as a more effective reminder to monitor weight, blood pressure, glucose, international normalized ratio (INR), vaccinations, and medication adherence? Behavioral health may prove to be another dimension of precision medicine, one that is characterized by designing feedback systems or incentives tailored specifically to individual patients.³⁴

In this article, we have highlighted the convergence of a variety of technological breakthroughs that are accelerating the field of precision medicine. The extent to which these advances are constructive or disruptive depends on our ability to harness vast amounts of new knowledge and treatment options within the framework of everyday clinical practice (Fig. 2). Changes that occur will require reengineering and adaptations by multiple stakeholders.³⁵ Medical school curricula will need to focus even more on information management. Physicians will require informatics support and algorithms that work in the background to assist with information management and decision making. Health systems will need to design pathways that facilitate ready access to specialists when appropriate. Regulatory agencies and payers will need to evaluate and support, when appropriate, advances in precision medicine if patients are to receive maximum benefit. When the term precision medicine disappears from our lexicon, we will know that a revised disease classification with more targeted treatment options has become the norm.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

From the University of Pennsylvania Perelman School of Medicine, Philadelphia (J.L.J.).

This article was published on May 27, 2015, at NEJM.org.

- Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med* 2015;372:793-5.
- Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. *N Engl J Med* 2014;371:1994-2004.
- Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;363:1693-703.
- Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med* 2006;355:2408-17.
- Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. *Lancet* 1994;344:1453-7.

6. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. *N Engl J Med* 2011;364:1943-54.
7. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. *N Engl J Med* 2009;360:363-75.
8. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* 2011;365:1663-72.
9. Suthanthiran M, Schwartz JE, Ding R, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. *N Engl J Med* 2013;369:20-31.
10. Liang TJ, Ghany MG. Therapy of hepatitis C — back to the future. *N Engl J Med* 2014;370:2043-7.
11. Moore FD, Dluhy RG. Prophylactic thyroidectomy in MEN-2A — a stitch in time? *N Engl J Med* 2005;353:1162-4.
12. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;129:Suppl 2: S1-S45.
13. Leypfold F, Höftberger R, Titulaer MJ, et al. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response. *JAMA Neurol* 2015; 72:180-6.
14. Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. *Am J Psychiatry* 2014;171:445-52.
15. Lerman C, Schnoll RA, Hawk LW Jr, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. *Lancet Respir Med* 2015;3:131-8.
16. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. *N Engl J Med* 2008;358:2240-8.
17. Committee on a Framework for Developing a New Taxonomy of Disease, National Research Council. *Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease*. Washington, DC: National Academies Press, 2011.
18. Hayden EC. Technology: the \$1,000 genome. *Nature* 2014; 507:294-5.
19. Lander ES. Cutting the Gordian helix — regulating genomic testing in the era of precision medicine. *N Engl J Med* 2015;372: 1185-6.
20. Paulson EK, Kalady MF, Pappas TN. Suspected appendicitis. *N Engl J Med* 2003;348:236-42.
21. Evens AM, Kostakoglu L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. *Blood* 2014;124:3356-64.
22. Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. *Curr Drug Metab* 2014;15:209-17.
23. Jameson JL. 2014 Association of American Physicians presidential address: disruptive innovation as a driver of science and medicine. *J Clin Invest* 2014;124:2822-6.
24. Rubin R. Precision medicine: the future or simply politics? *JAMA* 2015;313:1089-91.
25. Capell BC, Collins FS. Human laminopathies: nuclei gone genetically awry. *Nat Rev Genet* 2006;7:940-52.
26. Siman R, Giovannone N, Hanten G, et al. Evidence that the blood biomarker SNTF predicts brain imaging changes and persistent cognitive dysfunction in mild TBI patients. *Front Neurol* 2013;4:190.
27. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. *Lancet Neurol* 2010;9:363-72.
28. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. *N Engl J Med* 2013;368:1199-209.
29. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med* 2010;363: 809-19.
30. Hudis CA. Trastuzumab — mechanism of action and use in clinical practice. *N Engl J Med* 2007;357:39-51.
31. Ribas A. Tumor immunotherapy directed at PD-1. *N Engl J Med* 2012;366:2517-9.
32. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med* 2011;365:725-33.
33. Blaser MJ. The microbiome revolution. *J Clin Invest* 2014;124: 4162-5.
34. Asch DA, Muller RW, Volpp KG. Automated hovering in health care — watching over the 5000 hours. *N Engl J Med* 2012;367:1-3.
35. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. *N Engl J Med* 2012;366:489-91.

DOI: 10.1056/NEJMsb1503104

Copyright © 2015 Massachusetts Medical Society.

MY NEJM IN THE JOURNAL ONLINE

Individual subscribers can store articles and searches using a feature on the *Journal's* website (NEJM.org) called "My NEJM."

Each article and search result links to this feature. Users can create personal folders and move articles into them for convenient retrieval later.